Clinical significance of tubular and podocyte biomarkers in acute kidney injury

Katsuomi Matsui, Atsuko Kamijo-Ikemori, Masanori Hara, Takeshi Sugaya, Takamitsu Kodama, Sigeki Fujitani, Yasuhiko Taira, Takashi Yasuda, Kenjiro Kimura

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: Acute kidney injury (AKI) is a common complication in critically ill patients. Urinary excretion of liver-type fatty acid-binding protein (L-FABP), which is expressed in the proximal tubules, reflects the presence of tubular injury. Urinary excretion of podocalyxin (PCX), a glycoprotein prominently expressed on podocytes, is associated with podocyte injury. Our aims were to evaluate the utility of urinary L-FABP for the early detection of AKI and to examine whether podocyte injury is present in AKI patients using the biomarker of urinary PCX. Methods: Patients admitted to the intensive care unit (ICU) were divided into the AKI group (n = 14) and non-AKI group (n = 11), according to the occurrence of AKI during hospitalization in the ICU. Changes in various biomarkers were evaluated. Results: In the AKI group, elevation of urinary L-FABP level [maximum value of L-FABP, 199.0 (92.5-433.6) μg/g creatinine, median (25-75% interquartile range)], which reflects tubular injury (area under the curve 0.95, cut-off value 44.1 μg/g Cr), occurred between -30 and 0 h before the occurrence of AKI (i.e., the time at which serum creatinine peaked), and elevation of urinary PCX level [maximum value of PCX, 389.5 (267.0-501.0) μg/g creatinine; upper limit of reference value, 160 μg/g creatinine] occurred during the time of recovery from AKI when serum creatinine levels were decreasing between 34.0 and 72.0 h after the occurrence of AKI. Furthermore, a parameter with the primary large AUC for predicting the onset of AKI was urinary L-FABP. Conclusions: Our study suggests that L-FABP is a useful biomarker for early detection of AKI and that podocyte injury was induced during the recovery phase of AKI.

Original languageEnglish (US)
Pages (from-to)220-225
Number of pages6
JournalClinical and Experimental Nephrology
Volume15
Issue number2
DOIs
StatePublished - Apr 2011

Fingerprint

Podocytes
Acute Kidney Injury
Biomarkers
Fatty Acid-Binding Proteins
Creatinine
Wounds and Injuries
Area Under Curve
Intensive Care Units
Serum
Critical Illness
Glycoproteins
Reference Values
Hospitalization

Keywords

  • Acute kidney injury (AKI)
  • Liver-type fatty acid-binding protein (L-FABP)
  • Podocalyxin (PCX)
  • Podocyte injury

ASJC Scopus subject areas

  • Nephrology
  • Physiology
  • Physiology (medical)

Cite this

Matsui, K., Kamijo-Ikemori, A., Hara, M., Sugaya, T., Kodama, T., Fujitani, S., ... Kimura, K. (2011). Clinical significance of tubular and podocyte biomarkers in acute kidney injury. Clinical and Experimental Nephrology, 15(2), 220-225. https://doi.org/10.1007/s10157-010-0384-y

Clinical significance of tubular and podocyte biomarkers in acute kidney injury. / Matsui, Katsuomi; Kamijo-Ikemori, Atsuko; Hara, Masanori; Sugaya, Takeshi; Kodama, Takamitsu; Fujitani, Sigeki; Taira, Yasuhiko; Yasuda, Takashi; Kimura, Kenjiro.

In: Clinical and Experimental Nephrology, Vol. 15, No. 2, 04.2011, p. 220-225.

Research output: Contribution to journalArticle

Matsui, K, Kamijo-Ikemori, A, Hara, M, Sugaya, T, Kodama, T, Fujitani, S, Taira, Y, Yasuda, T & Kimura, K 2011, 'Clinical significance of tubular and podocyte biomarkers in acute kidney injury', Clinical and Experimental Nephrology, vol. 15, no. 2, pp. 220-225. https://doi.org/10.1007/s10157-010-0384-y
Matsui, Katsuomi ; Kamijo-Ikemori, Atsuko ; Hara, Masanori ; Sugaya, Takeshi ; Kodama, Takamitsu ; Fujitani, Sigeki ; Taira, Yasuhiko ; Yasuda, Takashi ; Kimura, Kenjiro. / Clinical significance of tubular and podocyte biomarkers in acute kidney injury. In: Clinical and Experimental Nephrology. 2011 ; Vol. 15, No. 2. pp. 220-225.
@article{6794d63b833f429b83a386760d5d651a,
title = "Clinical significance of tubular and podocyte biomarkers in acute kidney injury",
abstract = "Background: Acute kidney injury (AKI) is a common complication in critically ill patients. Urinary excretion of liver-type fatty acid-binding protein (L-FABP), which is expressed in the proximal tubules, reflects the presence of tubular injury. Urinary excretion of podocalyxin (PCX), a glycoprotein prominently expressed on podocytes, is associated with podocyte injury. Our aims were to evaluate the utility of urinary L-FABP for the early detection of AKI and to examine whether podocyte injury is present in AKI patients using the biomarker of urinary PCX. Methods: Patients admitted to the intensive care unit (ICU) were divided into the AKI group (n = 14) and non-AKI group (n = 11), according to the occurrence of AKI during hospitalization in the ICU. Changes in various biomarkers were evaluated. Results: In the AKI group, elevation of urinary L-FABP level [maximum value of L-FABP, 199.0 (92.5-433.6) μg/g creatinine, median (25-75{\%} interquartile range)], which reflects tubular injury (area under the curve 0.95, cut-off value 44.1 μg/g Cr), occurred between -30 and 0 h before the occurrence of AKI (i.e., the time at which serum creatinine peaked), and elevation of urinary PCX level [maximum value of PCX, 389.5 (267.0-501.0) μg/g creatinine; upper limit of reference value, 160 μg/g creatinine] occurred during the time of recovery from AKI when serum creatinine levels were decreasing between 34.0 and 72.0 h after the occurrence of AKI. Furthermore, a parameter with the primary large AUC for predicting the onset of AKI was urinary L-FABP. Conclusions: Our study suggests that L-FABP is a useful biomarker for early detection of AKI and that podocyte injury was induced during the recovery phase of AKI.",
keywords = "Acute kidney injury (AKI), Liver-type fatty acid-binding protein (L-FABP), Podocalyxin (PCX), Podocyte injury",
author = "Katsuomi Matsui and Atsuko Kamijo-Ikemori and Masanori Hara and Takeshi Sugaya and Takamitsu Kodama and Sigeki Fujitani and Yasuhiko Taira and Takashi Yasuda and Kenjiro Kimura",
year = "2011",
month = "4",
doi = "10.1007/s10157-010-0384-y",
language = "English (US)",
volume = "15",
pages = "220--225",
journal = "Clinical and Experimental Nephrology",
issn = "1342-1751",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Clinical significance of tubular and podocyte biomarkers in acute kidney injury

AU - Matsui, Katsuomi

AU - Kamijo-Ikemori, Atsuko

AU - Hara, Masanori

AU - Sugaya, Takeshi

AU - Kodama, Takamitsu

AU - Fujitani, Sigeki

AU - Taira, Yasuhiko

AU - Yasuda, Takashi

AU - Kimura, Kenjiro

PY - 2011/4

Y1 - 2011/4

N2 - Background: Acute kidney injury (AKI) is a common complication in critically ill patients. Urinary excretion of liver-type fatty acid-binding protein (L-FABP), which is expressed in the proximal tubules, reflects the presence of tubular injury. Urinary excretion of podocalyxin (PCX), a glycoprotein prominently expressed on podocytes, is associated with podocyte injury. Our aims were to evaluate the utility of urinary L-FABP for the early detection of AKI and to examine whether podocyte injury is present in AKI patients using the biomarker of urinary PCX. Methods: Patients admitted to the intensive care unit (ICU) were divided into the AKI group (n = 14) and non-AKI group (n = 11), according to the occurrence of AKI during hospitalization in the ICU. Changes in various biomarkers were evaluated. Results: In the AKI group, elevation of urinary L-FABP level [maximum value of L-FABP, 199.0 (92.5-433.6) μg/g creatinine, median (25-75% interquartile range)], which reflects tubular injury (area under the curve 0.95, cut-off value 44.1 μg/g Cr), occurred between -30 and 0 h before the occurrence of AKI (i.e., the time at which serum creatinine peaked), and elevation of urinary PCX level [maximum value of PCX, 389.5 (267.0-501.0) μg/g creatinine; upper limit of reference value, 160 μg/g creatinine] occurred during the time of recovery from AKI when serum creatinine levels were decreasing between 34.0 and 72.0 h after the occurrence of AKI. Furthermore, a parameter with the primary large AUC for predicting the onset of AKI was urinary L-FABP. Conclusions: Our study suggests that L-FABP is a useful biomarker for early detection of AKI and that podocyte injury was induced during the recovery phase of AKI.

AB - Background: Acute kidney injury (AKI) is a common complication in critically ill patients. Urinary excretion of liver-type fatty acid-binding protein (L-FABP), which is expressed in the proximal tubules, reflects the presence of tubular injury. Urinary excretion of podocalyxin (PCX), a glycoprotein prominently expressed on podocytes, is associated with podocyte injury. Our aims were to evaluate the utility of urinary L-FABP for the early detection of AKI and to examine whether podocyte injury is present in AKI patients using the biomarker of urinary PCX. Methods: Patients admitted to the intensive care unit (ICU) were divided into the AKI group (n = 14) and non-AKI group (n = 11), according to the occurrence of AKI during hospitalization in the ICU. Changes in various biomarkers were evaluated. Results: In the AKI group, elevation of urinary L-FABP level [maximum value of L-FABP, 199.0 (92.5-433.6) μg/g creatinine, median (25-75% interquartile range)], which reflects tubular injury (area under the curve 0.95, cut-off value 44.1 μg/g Cr), occurred between -30 and 0 h before the occurrence of AKI (i.e., the time at which serum creatinine peaked), and elevation of urinary PCX level [maximum value of PCX, 389.5 (267.0-501.0) μg/g creatinine; upper limit of reference value, 160 μg/g creatinine] occurred during the time of recovery from AKI when serum creatinine levels were decreasing between 34.0 and 72.0 h after the occurrence of AKI. Furthermore, a parameter with the primary large AUC for predicting the onset of AKI was urinary L-FABP. Conclusions: Our study suggests that L-FABP is a useful biomarker for early detection of AKI and that podocyte injury was induced during the recovery phase of AKI.

KW - Acute kidney injury (AKI)

KW - Liver-type fatty acid-binding protein (L-FABP)

KW - Podocalyxin (PCX)

KW - Podocyte injury

UR - http://www.scopus.com/inward/record.url?scp=79959270411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959270411&partnerID=8YFLogxK

U2 - 10.1007/s10157-010-0384-y

DO - 10.1007/s10157-010-0384-y

M3 - Article

C2 - 21153750

AN - SCOPUS:79959270411

VL - 15

SP - 220

EP - 225

JO - Clinical and Experimental Nephrology

JF - Clinical and Experimental Nephrology

SN - 1342-1751

IS - 2

ER -